Biotech
Now That's An Impurity Story
Publication: AAAS: Keyword search for query
Author: Not available in collected metadata
Source published: 28/09/2026, 02:02:38 UTC
Briefing created: 28/09/2026, 18:45:51 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 18:19:30 UTC.
Briefings
A recent study identified a recurring impurity in efinaconazole batches at 0.06%, caused by a single deuterium atom replacing a hydrogen in the piperidine ring. This deuterium isomerization creates a physical property change that alters HPLC retention time, leading to a false peak in LC analysis. The impurity originates from the natural abundance of deuterium (0.015%) during synthesis, not from starting materials or reaction conditions. High-resolution Orbitrap mass spectrometry confirmed the deuterium assignment, while NMR spectroscopy verified the specific methylene position. The authors note that despite extensive purification attempts, the impurity persists, suggesting an intrinsic molecular property rather than a process issue.
Key points
- The impurity is a deuterium isomer in the piperidine ring of efinaconazole, present at 0.06% of samples.
- The deuterium substitution alters HPLC retention time, causing a false peak that mimics the drug's elution profile.
Context and limitations
The study relies on LC and Orbitrap mass spectrometry data; NMR confirmation was limited to specific isomers. The authors acknowledge the difficulty of identifying the source and note that the exact origin of the deuterium remains unexplained, though natural abundance is cited as the likely source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 18:45:51 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeic4jtsguhkufxkdwe2nc4wz2tslxujg4yxnnrtj5q3wtm27wwdepa